No Data
No Data
Puli Pharmaceuticals (300630.SZ) obtained GMP certification from Saudi Arabian Food and Drug Administration
Puli Pharmaceuticals (300630.SZ) issued an announcement. The company recently received from the Saudi Food and Drug Administration (...
Bipli Pharmaceuticals (300630.SZ) has not completed its self-inspection of the previous report and is unable to disclose the regular report on schedule. Stock and bond trading was suspended from May 6
Puri Pharmaceuticals (300630.SZ) issued an announcement that the company was unable to meet the legal deadline (April 30, 2024...
Puli Pharmaceuticals: “Priori Bonds” will be suspended from trading and stock conversion will be suspended from May 6, 2024
Hainan Puli Pharmaceutical Co., Ltd. announced that due to the inability of Hainan Puli Pharmaceutical Co., Ltd. to disclose the 2023 annual report and the first quarter report of 2024 within the legal period (April 30, 2024), trading of the company's shares and convertible corporate bonds (bond abbreviation: Pulley Convertible, Bond Code: 123099) will be suspended from May 6, 2024. According to regulations: “Where stock trading of a listed company is suspended and resumed, trading of its convertible bonds is suspended or resumed at the same time.” As a result, during the stock suspension period, “Pulley Convertible Bonds” was suspended and stock conversion was suspended.
Express News | Puli Pharmaceuticals: Unable to disclose the 2023 Annual Report and the suspension of trading of stocks and convertible bonds reported for the first quarter of 2024 within the statutory period
The China Securities Convertible Index opened up 0.06%. Kai Convertible Bonds rose more than 8%, Zhengdan Convertible bonds rose 5%, and Puli Convertible bonds fell by more than 8%.
The China Securities Convertible Index opened up 0.06%. Kai Convertible Bonds rose more than 8%, Zhengdan Convertible bonds rose 5%, and Puli Convertible bonds fell by more than 8%.
China Securities Peng Yuan: Concerned that Puli Pharmaceuticals has received a decision on administrative supervision measures
China Securities Peng Yuan is concerned that according to the “Notice of Hainan Puli Pharmaceutical Co., Ltd. on Receiving the Hainan Securities Regulatory Bureau's Decision to Order the Company to Correct Administrative Supervision Measures” issued by Puli Pharmaceuticals on April 16, 2024, the Hainan Securities Regulatory Bureau issued a “Decision on Ordering Corrective Measures against Hainan Puli Pharmaceutical Co., Ltd.”, decided to take corrective administrative supervision measures against the company, and recorded the relevant irregularities in the capital market integrity file database. At the same time, the company was required to submit a rectification report to the Hainan Securities Regulatory Bureau within 30 days from the date of receipt of the decision. Depending on the follow-up inspection, the Supervisory Authority will review
No Data